Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboxyamidotriazole soft capsules plus osimertinib versus osimertinib as first-line treatment for EGFR-mutant advanced non-small cell lung cancer with bone metastases
CTR20261504Phase 2Active
- Sponsor
- Yinzhu Pharmaceutical
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Carboxyamidotriazole + osimertinib with Osimertinib control (2 arms). Primary endpoints: Dose-limiting toxicity and Progression-free survival. Started Apr 2026; status: active.
02
Drugs
carboxyamidotriazoleosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261504.